Every record from Medutest · page 5
Fast turnaround and the widest compound acceptance, at unit mass resolution rather than high resolution. Measured offset against the reference laboratory is +0.065 pp on 517 paired lots. Full laboratory profile →
| Report | Compound | Supplier | Lot | Quarter | Purity % | Water % | Recovery % | Provenance | Flags | Result |
|---|---|---|---|---|---|---|---|---|---|---|
| AX-2026-042756 | TB-500 | GGPeps | GGPE-2601-B9932 | 2026-Q2 | 99.79 | 4.79 | — | Supplier-supplied | 1 | MARGINAL |
| AX-2026-041802 | Tirzepatide | FGP | FGP-2605-R1831 | 2026-Q2 | 98.07 | 6.43 | — | Supplier-supplied | 2 | MARGINAL |
| AX-2026-043001 | TB-500 | KP | KP-2605-C4659 | 2026-Q2 | 99.33 | 5.74 | — | Supplier-supplied | 2 | MARGINAL |
| AX-2026-042566 | Tirzepatide | ERP | ERP-2512-T7433 | 2026-Q2 | 99.36 | 1.63 | 99.6 | Supplier-supplied | 2 | MARGINAL |
| AX-2026-042017 | Liraglutide | TFC | TFC-2511-E6528 | 2026-Q2 | 98.38 | 3.92 | 103.5 | Supplier-supplied | 0 | PASS |
| AX-2026-043387 | Melanotan II | CPC | CPC-2605-U3868 | 2026-Q2 | 98.55 | 3.15 | — | Supplier-supplied | 2 | MARGINAL |
| AX-2026-042322 | Tirzepatide | HJ | HJ-2605-D3120 | 2026-Q2 | 98.83 | 4.41 | — | Supplier-supplied | 3 | MARGINAL |
| AX-2026-043339 | Retatrutide | CPC | CPC-2604-H2730 | 2026-Q2 | 96.19 | 4.12 | — | Supplier-supplied | 2 | FAIL |
| AX-2026-043434 | Semaglutide | WXT | WXT-2602-G4442 | 2026-Q2 | 97.66 | 5.36 | 98.1 | Supplier-supplied | 1 | MARGINAL |
| AX-2026-042638 | IGF-1 LR3 | GGPeps | GGPE-2604-K8140 | 2026-Q2 | 97.47 | 2.69 | 96.0 | Supplier-supplied | 0 | PASS |
| AX-2026-042358 | Sermorelin | HJ | HJ-2605-A4196 | 2026-Q2 | 99.20 | 5.83 | — | Supplier-supplied | 0 | PASS |
| AX-2026-041703 | Hexarelin | QSC | QSC-2601-N9656 | 2026-Q2 | 99.77 | 5.65 | 103.3 | Supplier-supplied | 0 | PASS |
| AX-2026-043093 | Epitalon | KP | KP-2512-R5829 | 2026-Q2 | 98.39 | 6.17 | 107.0 | Supplier-supplied | 2 | FAIL |
| AX-2026-042565 | Tirzepatide | ERP | ERP-2512-T7433 | 2026-Q2 | 98.87 | 1.96 | — | Supplier-supplied | 2 | MARGINAL |
| AX-2026-043082 | Tirzepatide | KP | KP-2605-E6030 | 2026-Q2 | 98.25 | 4.08 | 103.5 | Supplier-supplied | 1 | MARGINAL |
| AX-2026-043022 | Semaglutide | KP | KP-2511-J4998 | 2026-Q2 | 99.86 | 8.37 | — | Supplier-supplied | 1 | FAIL |
| AX-2026-042295 | AOD-9604 | HJ | HJ-2601-N2483 | 2026-Q2 | 98.88 | 5.80 | 93.8 | Supplier-supplied | 1 | MARGINAL |
| AX-2026-041369 | Semaglutide | WWB | WWB-2512-T3671 | 2026-Q2 | 99.57 | 3.34 | — | Supplier-supplied | 1 | MARGINAL |
| AX-2026-043121 | Mazdutide | SSA | SSA-2605-G6781 | 2026-Q2 | 98.79 | 2.52 | — | Supplier-supplied | 1 | MARGINAL |
| AX-2026-042586 | SLU-PP-332 | GGPeps | GGPE-2511-R8569 | 2026-Q2 | 98.35 | 4.78 | 101.6 | Buyer-sourced | 1 | MARGINAL |
| AX-2026-042933 | Semaglutide | MKM | MKM-2601-Y3343 | 2026-Q2 | 98.25 | 3.50 | — | Supplier-supplied | 3 | FAIL |
| AX-2026-042123 | ARA-290 | Homopeptide | HOMO-2601-T8238 | 2026-Q2 | 99.93 | 3.40 | 102.7 | Supplier-supplied | 0 | PASS |
| AX-2026-041462 | SS-31 (Elamipretide) | QYB | QYB-2512-H5402 | 2026-Q2 | 98.98 | 4.73 | 98.6 | Supplier-supplied | 1 | MARGINAL |
| AX-2026-043519 | MGF | BCH | BCH-2511-D7240 | 2026-Q2 | 98.87 | 6.14 | — | Laboratory-retained | 1 | FAIL |
| AX-2026-042034 | Gonadorelin | TFC | TFC-2511-E6450 | 2026-Q2 | 99.81 | 2.67 | — | Supplier-supplied | 0 | PASS |
| AX-2026-042625 | KPV | GGPeps | GGPE-2511-K8830 | 2026-Q2 | 98.78 | 4.69 | — | Supplier-supplied | 1 | FAIL |
| AX-2026-041828 | BPC-157 | FGP | FGP-2601-E2289 | 2026-Q2 | 98.97 | 3.42 | — | Supplier-supplied | 1 | MARGINAL |
| AX-2026-041304 | Ipamorelin | WWB | WWB-2604-E3153 | 2026-Q2 | 99.93 | 6.34 | 100.6 | Supplier-supplied | 1 | FAIL |
| AX-2026-042761 | TB-500 | GGPeps | GGPE-2601-B9932 | 2026-Q2 | 99.44 | 4.46 | — | Supplier-supplied | 1 | MARGINAL |
| AX-2026-041827 | BPC-157 | FGP | FGP-2601-E2289 | 2026-Q2 | 99.93 | 3.60 | — | Supplier-supplied | 1 | MARGINAL |
| AX-2026-041750 | Cagrilintide | FGP | FGP-2602-M9870 | 2026-Q2 | 98.58 | 3.43 | 93.1 | Supplier-supplied | 0 | PASS |
| AX-2026-042025 | Ipamorelin | TFC | TFC-2603-M6766 | 2026-Q2 | 99.93 | 4.68 | — | Supplier-supplied | 0 | PASS |
| AX-2026-043389 | Melanotan II | CPC | CPC-2605-U3868 | 2026-Q2 | 99.19 | 3.70 | — | Supplier-supplied | 2 | MARGINAL |
| AX-2026-042731 | Survodutide | GGPeps | GGPE-2512-Y9921 | 2026-Q2 | 97.90 | 3.68 | — | Supplier-supplied | 1 | MARGINAL |
| AX-2026-043165 | Retatrutide | SSA | SSA-2601-T7702 | 2026-Q1 | 98.85 | 4.89 | 105.4 | Supplier-supplied | 2 | MARGINAL |
| AX-2026-042569 | GHK-Cu | ERP | ERP-2604-K8139 | 2026-Q2 | 98.34 | 6.96 | — | Supplier-supplied | 1 | MARGINAL |
| AX-2026-042522 | Liraglutide | ERP | ERP-2601-P6802 | 2026-Q2 | 98.21 | 4.94 | 101.3 | Supplier-supplied | 1 | MARGINAL |
| AX-2026-043162 | Retatrutide | SSA | SSA-2601-T7702 | 2026-Q1 | 98.70 | 5.82 | 106.4 | Supplier-supplied | 3 | FAIL |
| AX-2026-042892 | Semaglutide | MKM | MKM-2510-S2813 | 2026-Q1 | 99.49 | 6.51 | 93.0 | Supplier-supplied | 1 | MARGINAL |
| AX-2026-042312 | Tirzepatide | HJ | HJ-2508-P3416 | 2026-Q1 | 98.04 | 4.86 | 100.1 | Supplier-supplied | 3 | MARGINAL |